Literature DB >> 19389922

In vivo and in vitro structure-activity relationships and structural conformation of Kisspeptin-10-related peptides.

Ester Gutiérrez-Pascual1, Jérôme Leprince, Antonio J Martínez-Fuentes, Isabelle Ségalas-Milazzo, Rafael Pineda, Juan Roa, Mario Duran-Prado, Laure Guilhaudis, Elia Desperrois, Aurélie Lebreton, Leonor Pinilla, Marie-Christine Tonon, María M Malagón, Hubert Vaudry, Manuel Tena-Sempere, Justo P Castaño.   

Abstract

Kisspeptins, the natural ligands of the G protein-coupled receptor KISS1R, comprise a family of related peptides derived from the proteolytic processing of a common precursor encoded by the KISS1 gene. Among those, Kisspeptin-10 (Kp-10) contains the basic residues to retain full functional activity and exhibits higher receptor affinity and biopotency than longer forms of the peptide. Although kisspeptins were first characterized by their ability to inhibit tumor metastasis, recent studies have revealed that the KISS1/KISS1R system plays an essential role in the neuroendocrine control of the reproductive axis. In this context, development and functional analysis of Kp-10 analogs may help in the search for new agonists and antagonists as valuable tools to manipulate the KISS1/KISS1R system and hence fertility. We report herein functional and structural analyses of a series of Ala-substituted rat kp-10 analogs, involving [Ca(2+)](i) responses in rat kiss1r-transfected Chinese hamster ovary cells, dynamic luteinizing hormone (LH) responses in vivo, and NMR structural studies. In vitro assays revealed that Ala substitutions in positions 6 or 10 of kp-10 resulted in a significant increase in EC(50) values (>6.46 x 10(-6) M versus 1.54 to 2.6 x 10(-8) M for rat and human Kp-10, respectively) and a substantial decrease in the proportion of responsive cells coupled to a marked increase in the time required to reach maximal response. In vivo assays showed that Ala(6) substitution diminished and Ala(10) substitution eliminated LH secretory responses, whereas coadministration of each analog failed to affect the LH-releasing ability of kp-10. Molecular modeling under NMR restraints revealed that kp-10 exhibits a helicoidal structure between the Asn(4) and Tyr(10) residues, with mixed alpha- and 3(10)-helix characteristics. Ala(6) substitution induced limited destabilization of the helix around the position of the substitution. Ala(10) substitution was found to totally disrupt the helical structure in the C-terminal region of the molecule. Taken together, our results indicate that positions 6 and 10 are critical for kp-10 action at kiss1r and suggest that modifications in these positions could lead to the generation of new kisspeptin agonists and/or antagonists with altered functional and perhaps binding properties. Furthermore, they emphasize the importance of using combined, multidisciplinary approaches, including in vivo studies, to reliably evaluate structure function properties of novel kisspeptin analogs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389922     DOI: 10.1124/mol.108.053751

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor nomenclature, distribution, and function.

Authors:  Helen R Kirby; Janet J Maguire; William H Colledge; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  General lack of structural characterization of chemically synthesized long peptides.

Authors:  Jean A Boutin; André L Tartar; Alain van Dorsselaer; Hubert Vaudry
Journal:  Protein Sci       Date:  2019-03-25       Impact factor: 6.725

3.  Activation of Neuropeptide FF Receptors by Kisspeptin Receptor Ligands.

Authors:  Shinya Oishi; Ryosuke Misu; Kenji Tomita; Shohei Setsuda; Ryo Masuda; Hiroaki Ohno; Yousuke Naniwa; Nahoko Ieda; Naoko Inoue; Satoshi Ohkura; Yoshihisa Uenoyama; Hiroko Tsukamura; Kei-Ichiro Maeda; Akira Hirasawa; Gozoh Tsujimoto; Nobutaka Fujii
Journal:  ACS Med Chem Lett       Date:  2010-10-25       Impact factor: 4.345

4.  Classical and membrane-initiated estrogen signaling in an in vitro model of anterior hypothalamic kisspeptin neurons.

Authors:  Melinda A Mittelman-Smith; Angela M Wong; Anupama S Q Kathiresan; Paul E Micevych
Journal:  Endocrinology       Date:  2015-03-02       Impact factor: 4.736

5.  A high-throughput small-molecule ligand screen targeted to agonists and antagonists of the G-protein-coupled receptor GPR54.

Authors:  Wendy Kuohung; Maria Burnett; Deepa Mukhtyar; Eli Schuman; Jake Ni; William F Crowley; Marcie A Glicksman; Ursula B Kaiser
Journal:  J Biomol Screen       Date:  2010-05-10

Review 6.  Kisspeptin signaling in the brain.

Authors:  Amy E Oakley; Donald K Clifton; Robert A Steiner
Journal:  Endocr Rev       Date:  2009-09-21       Impact factor: 19.871

7.  EP24.15 as a Potential Regulator of Kisspeptin Within the Neuroendocrine Hypothalamus.

Authors:  Nicole C Woitowich; Keith D Philibert; Randy J Leitermann; Manida Wungjiranirun; Janice H Urban; Marc J Glucksman
Journal:  Endocrinology       Date:  2015-12-11       Impact factor: 4.736

Review 8.  Current and future applications of GnRH, kisspeptin and neurokinin B analogues.

Authors:  Robert P Millar; Claire L Newton
Journal:  Nat Rev Endocrinol       Date:  2013-07-02       Impact factor: 43.330

9.  Molecular identification of Kiss/GPR54 and function analysis with mRNA expression profiles exposure to 17α-ethinylestradiol in rare minnow Gobiocypris rarus.

Authors:  Yanping Yang; Jiancao Gao; Cong Yuan; Yingying Zhang; Yongjing Guan; Zaizhao Wang
Journal:  Mol Biol Rep       Date:  2016-05-23       Impact factor: 2.316

10.  A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10.

Authors:  Annette E Curtis; Jennifer H Cooke; Jordan E Baxter; James R C Parkinson; Attia Bataveljic; Mohammad A Ghatei; Stephen R Bloom; Kevin G Murphy
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-24       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.